CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer Center, and founder of the Institute for Myeloma & Bone Cancer Research, about toxicities associated with ruxolitinib (Jakafi) combination therapy, as well as strategies for reducing them. Additionally, the synergistic effects of adding ruxolitinib to selinexor were discussed.
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...